| Document |
Document Title |
|
WO/2024/083856A1 |
The present invention concerns a two-phase formulation comprising (i) a primary powder phase comprising a still alive strain of probiotic bacteria in a freeze-dried state and at least one gelifying agent, and (ii) a complementary aqueous...
|
|
WO/2024/085695A1 |
The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
|
|
WO/2024/083930A1 |
The invention relates to a topically applied preparation comprising a combination of substances including antimicrobial peptides (AMP), in particular cyclic peptide compounds based on the synthesis of thiazolidine and oxazolidine compone...
|
|
WO/2024/083801A1 |
The invention relates to a foam having a gas phase and an aqueous liquid phase, the gas phase making up at least 50 vol.% of the foam and substantially comprising hydrogen gas, and the aqueous liquid phase comprising at least one dissolv...
|
|
WO/2024/085417A1 |
The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata by acting as a functional inhibitor against S1P receptor subtypes S1PR1 and S1PR4, and, more particularly, to a pharmaceutical compo...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/086100A1 |
Methods and formulations for the systemic protection of an animal from exposure to a photocarcinogen. The methods include orally administering to an animal a formulation comprising a therapeutically effective amount of one or more UV-abs...
|
|
WO/2024/082014A1 |
The present invention relates to compositions comprising cannabidiolic acid and fatty acids; pharmaceuticals, nutraceuticals, medical foods, dietary supplements, functional foods, animal foods and dosage forms comprising this composition...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/085315A1 |
According to a human fibroblast culture fluid complex (G4PRF-300) effective for regenerating human tissues, a preparation method therefor, and a topical liquid composition containing same, proposed in the present invention, 26 complex gr...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/083210A1 |
Among other things, the present disclosure provides compounds, e.g., of formula I or salts thereof. In some embodiments, the present disclosure provides methods for modulating MRGPRX4 activity. In some embodiments, the present disclosure...
|
|
WO/2024/085197A1 |
The present invention addresses the problem of providing a biocompatible carrier material capable of locally releasing a particulate substance. It is found that a carrier material comprising a non-gel polymer having multiple hydrophili...
|
|
WO/2024/084398A2 |
The present disclosure relates generally to polynucleotides, vectors, and cells for producing alpha 2 macroglobulin (A2M), methods of making A2M, and compositions comprising A2M. The present disclosure relates generally to polynucleotide...
|
|
WO/2024/083413A1 |
The invention relates to a topically applied preparation comprising a combination of substances including antimicrobial peptides (AMP), in particular cyclic peptide compounds based on the synthesis of thiazolidine and oxazolidine compone...
|
|
WO/2024/083847A1 |
The present invention provides an isolated antibody or antibody derivative that specifically binds to an equine interleukine-5 (eqIL-5) comprising at least one member selected from a group consisting of equine constant light chain, equin...
|
|
WO/2024/086348A1 |
Compositions, kits and methods are provided for preserving skin health. In general, retinoids, along with antioxidants, emollients, emulsifiers, moisturizer, and preservative are included in a physiologically acceptable medium. The compo...
|
|
WO/2024/080398A1 |
The present invention relates to a peptide having activities to promote hair growth or to prevent or inhibit alopecia. The peptide of the present invention promotes the proliferation of hair follicle dermal papilla cells (HFDPC) and huma...
|
|
WO/2024/077862A1 |
The use of extracellular vesicles from ginger in the preparation of a drug for promoting the proliferation of hair follicle stem cells, which use involves a method for rapidly separating extracellular vesicles from ginger. The rapid sepa...
|
|
WO/2024/080399A1 |
The present invention relates to a peptide with the activity of promoting hair growth or preventing or inhibiting alopecia. The peptide of the present invention promotes the proliferation of human follicular dermal papilla cells (HFDPC),...
|
|
WO/2024/080402A1 |
The present invention relates to a peptide having activities of promoting hair growth or preventing or inhibiting hair loss. The peptide of the present invention has activities of promoting the proliferation of hair follicle dermal papil...
|
|
WO/2024/078534A1 |
An interfering RNA for inhibiting MLPH expression, which comprises: any one or more nucleotide sequences as shown in SEQ ID NOs: 1-20 or SEQ ID NOs: 27-38. The siRNA has good activity in inhibiting MLPH mRNA expression, with an inhibitio...
|
|
WO/2024/078588A1 |
A use of a compound represented by general formula (I) or a salt thereof in the preparation of a composition for skin aging repair, the skin aging repair comprising one or more of improving fibroblast activity, promoting keratinocyte pro...
|
|
WO/2024/078561A1 |
The present invention belongs to the technical fields of microorganisms and cosmetics, and particularly relates to a Bifidobacterium animalis strain and the use thereof. Experiments prove that a supernatant of a fermentation broth of the...
|
|
WO/2024/077977A1 |
The use of lithospermic acid in preparation of drugs used for treating diabetic ulcers, belonging to the technical field of diabetic ulcer drugs. It is first proposed that the traditional Chinese medicine monomer lithospermic acid has th...
|
|
WO/2024/080401A1 |
The present invention relates to a peptide which promotes hair growth and prevents or inhibits hair loss. The peptide of the present invention promotes the proliferation of hair follicle dermal papilla cells (HFDPC) and human hair outer ...
|
|
WO/2024/031059A3 |
The present disclosure relates to a method of inducing cellular rejuvenation and/or regeneration of a cell or tissue comprising contacting the cell with an effective amount of a protein or nucleic acid encoding a protein that induces cel...
|
|
WO/2024/079251A1 |
The present invention relates to the field of food supplementation, in particular to the field of nutraceuticals, more in particular to the use of a composition comprising oleuropein. More specifically, the present invention relates to t...
|
|
WO/2024/077506A1 |
Atovaquone is used for treating and preventing acute and chronic inflammatory diseases in mammals, including mast cell-mediated inflammatory diseases.
|
|
WO/2024/078283A1 |
The present invention belongs to the field of medicine, and specifically relates to crisaborole or a pharmaceutically acceptable salt aqueous solution composition thereof, comprising an amino acid or a derivative thereof. The crisaborole...
|
|
WO/2024/078468A1 |
The present invention relates to use of a stilbene derivative in the prevention and/or treatment of ulcers. A compound of formula (I) or a pharmaceutically acceptable salt thereof can effectively prevent or treat ulcers, and in particula...
|
|
WO/2024/080400A1 |
The present invention relates to a peptide having activity in promoting hair growth or preventing or suppressing alopecia. The peptide according to the present invention promotes the proliferation of hair follicle dermal papilla cells (H...
|
|
WO/2024/076921A1 |
An acne treatment composition that contains a mixture of rhamnolipid salts is disclosed. The composition has efficacy against C. acnes. Also disclosed is a method for controlling, treating, or preventing acne in a subject.
|
|
WO/2024/074116A1 |
The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.
|
|
WO/2024/075686A1 |
Provided is a skin resident flora improving agent useful for keeping the skin in a good condition. In the skin resident flora improving agent, sophorose is used. Sophorose is provided with a function of making it possible to encourage pr...
|
|
WO/2024/075044A1 |
The present invention relates to a liquid crystal emulsion comprising: i) a fatty phase containing: at least one mono- and diglyceride of C12-C22 fatty acids; at least one butter; at least one oil; at least one alkylpolyglucoside, in whi...
|
|
WO/2024/075968A1 |
The present invention relates to a composition for external application to the skin, having an excellent skin improvement effect.
|
|
WO/2024/074700A1 |
The present invention relates to topical compositions comprising an estetrol component and the use of said compositions to deliver an effective amount of an estetrol component to the skin, particularly for wound healing. Optionally, the ...
|
|
WO/2024/075844A1 |
The present disclosure provides a technique for examining the acquisition risk of an inflammatory skin disease, the severity or the degree of progression thereof. The present disclosure provides a method for analyzing a biological sample...
|
|
WO/2024/075809A1 |
The purpose of the present invention is to provide an antimicrobial agent having reduced allergy properties and containing recombinant psLAAO, and a method for producing this antimicrobial agent. This purpose is solved by an antimicrobia...
|
|
WO/2024/075937A1 |
The present invention relates to a composition comprising a fucoidan fermentation product, and use thereof for improving the condition of the skin. Since low-molecular weight fucoidan can be induced when fucoidan is fermented using a Lac...
|
|
WO/2024/076173A1 |
Disclosed are a composition for inducing differentiation of adipose-derived stem cells into dermal papilla cells, and a differentiation method using the composition. The composition for inducing differentiation and the differentiation me...
|
|
WO/2024/077310A1 |
A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases or conditions, and methods of using such preparations. The preparations may be a sublingual pill, an injection, ...
|
|
WO/2024/077018A2 |
Provided herein are methods of treatment and uses involving an immunomodulatory TACI-Fc fusion protein that exhibits neutralizing activity of BAFF and APRIL (or BAFF/ APRIL heterotrimers). The provided TACI-Fc protein may include variant...
|
|
WO/2024/067531A1 |
Provided is a dual-targeting compound against FAP and integrin αvβ3. The targeting compound and a radionuclide marker thereof can synergistically target a FAP target and an integrin αvβ3 target in tumors, such that the number of and ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068851A1 |
A novel process for preparation of crystalline forms and novel crystalline forms of 1-(8- bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-meth
ylazetidin-3-amine salts is provided along with pharmaceutical compositions comprising...
|
|
WO/2024/073013A1 |
The present disclosure is directed to topical compositions and methods for the treatment and/or amelioration of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation, including Dupuytren's disease, Dupu...
|
|
WO/2024/073721A1 |
Methods and postbiotic compositions which reduce fecal enzyme activity, as well as absorbent articles which comprise the postbiotic compositions are disclosed. The postbiotic compositions and absorbent articles of the present disclosure ...
|
|
WO/2024/069507A1 |
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphe
nyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
|
